These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 33776458)

  • 1. A Difference Between Bedtime and Pre-Breakfast Plasma Glucose Levels Indicates the Need for Prandial Insulin in Basal Insulin-Treated Type 2 Diabetic Patients with Normal Fasting Glucose.
    Kress S; Borck A; Zisman A; Bramlage P; Siegmund T
    Diabetes Metab Syndr Obes; 2021; 14():1215-1222. PubMed ID: 33776458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A higher blood glucose level pre-breakfast in comparison to bedtime is a contraindication for intensification of prandial insulin therapy in patients with type 2 diabetes - The impact of a negative BeAM value.
    Siegmund T; Borck A; Zisman A; Bramlage P; Kress S
    J Clin Transl Endocrinol; 2018 Dec; 14():34-38. PubMed ID: 30416973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BeAM value: an indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes mellitus receiving basal insulin.
    Zisman A; Morales F; Stewart J; Stuhr A; Vlajnic A; Zhou R
    BMJ Open Diabetes Res Care; 2016; 4(1):e000171. PubMed ID: 27110368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes.
    Nicolucci A; Ceriello A; Di Bartolo P; Corcos A; Orsini Federici M
    Diabetes Ther; 2020 Mar; 11(3):573-584. PubMed ID: 31873857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basal-prandial insulin delivery in type 2 diabetes mellitus via the V-Go: a novel continuous subcutaneous infusion device.
    Kapitza C; Fein S; Heinemann L; Schleusener D; Levesque S; Strange P
    J Diabetes Sci Technol; 2008 Jan; 2(1):40-6. PubMed ID: 19885176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus.
    Kuzuya T; Nakagawa S; Satoh J; Kanazawa Y; Iwamoto Y; Kobayashi M; Nanjo K; Sasaki A; Seino Y; Ito C; Shima K; Nonaka K; Kadowaki T;
    Diabetes Res Clin Pract; 2002 Jan; 55(1):65-85. PubMed ID: 11755481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
    Rosenstock J; Park G; Zimmerman J;
    Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basal insulin ameliorates post-breakfast hyperglycemia via suppression of post-breakfast proinsulin/C-peptide ratio and fasting serum free fatty acid levels in patients with type 2 diabetes.
    Ogiso K; Koriyama N; Obo T; Tokito A; Nishio Y
    Diabetol Int; 2021 Apr; 12(2):161-170. PubMed ID: 33786271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimates of the relative and absolute diurnal contributions of fasting and post-prandial plasma glucose over a range of hyperglycaemia in type 2 diabetes.
    Peter R; Dunseath G; Luzio SD; Owens DR
    Diabetes Metab; 2013 Sep; 39(4):337-42. PubMed ID: 23993831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.
    Lankisch MR; Ferlinz KC; Leahy JL; Scherbaum WA;
    Diabetes Obes Metab; 2008 Dec; 10(12):1178-85. PubMed ID: 19040645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of insulin glulisine and lispro on postprandial plasma glucose and lipid profile in Japanese patients with type 2 diabetes mellitus.
    Yamada M; Suzuki J; Nakaya T; Ichikawa M; Yamamoto K; Imagawa M; Sato S; Fujii M; Zenimaru Y; Konoshita T; Ishizuka T
    Diabetol Int; 2021 Jul; 12(3):330-335. PubMed ID: 34150441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of a basal-plus regimen with insulin glargine and insulin glulisine for elderly patients with high cardiovascular risk and type 2 diabetes mellitus.
    Gómez-Huelgas R; Sabán-Ruiz J; García-Román FJ; Quintela-Fernández N; Seguí-Ripoll JM; Bonilla-Hernández MV; Romero-Meliá G
    Rev Clin Esp (Barc); 2017 May; 217(4):201-206. PubMed ID: 28314656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EADSG Guidelines: Insulin Therapy in Diabetes.
    Silver B; Ramaiya K; Andrew SB; Fredrick O; Bajaj S; Kalra S; Charlotte BM; Claudine K; Makhoba A
    Diabetes Ther; 2018 Apr; 9(2):449-492. PubMed ID: 29508275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effect of insulin glulisine to insulin aspart on breakfast postprandial blood glucose levels in children with type 1 diabetes mellitus on multiple daily injections.
    Cemeroglu AP; Kleis L; Wood A; Parkes C; Wood MA; Davis AT
    Endocr Pract; 2013; 19(4):614-9. PubMed ID: 23425652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adding Prandial Insulin to Basal Insulin Plus Oral Antidiabetic Drugs in Chinese Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Single-Arm Study.
    Jin Y; Sun X; Zhao X; Zhu T
    Diabetes Ther; 2017 Jun; 8(3):611-621. PubMed ID: 28349442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL.
    Landgraf W; Owens DR; Frier BM; Zhang M; Bolli GB
    Diabetes Obes Metab; 2020 Mar; 22(3):315-323. PubMed ID: 31608548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial.
    Raz I; Wilson PW; Strojek K; Kowalska I; Bozikov V; Gitt AK; Jermendy G; Campaigne BN; Kerr L; Milicevic Z; Jacober SJ
    Diabetes Care; 2009 Mar; 32(3):381-6. PubMed ID: 19246588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal-Bolus Insulin: Phase 4 OPTIMIZE Study.
    Mathieu C; Weisnagel SJ; Stella P; Bruhwyler J; Alexandre K
    Diabetes Ther; 2020 Feb; 11(2):495-507. PubMed ID: 31925722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study.
    Božek T; Bilić-Ćurčić I; Berković MC; Gradišer M; Kurir TT; Majanović SK; Marušić S
    Diabetol Metab Syndr; 2018; 10():16. PubMed ID: 29563974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.